Carboxylic compound and medicine comprising the same

The technology of a compound, hydroxylauric acid, is applied in anhydride/acid/halide active ingredients, antipyretics, organic chemistry, etc., and can solve problems such as hypoglycemia and secondary ineffectiveness of sulfonylureas, induced lactic acid, poisoning, etc.

Inactive Publication Date: 2006-06-28
KOWA CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Insulin and sulfonylureas are often used in the drug treatment of diabetes, but as a side effect, hypoglycemia and sulfonylureas are secondary ineffective due to liver fatigue
Biguanides improve insulin sensitivity, barely correct hyperglycemia, but induce lactic acidosis
The thiazolidine series dia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Carboxylic compound and medicine comprising the same
  • Carboxylic compound and medicine comprising the same
  • Carboxylic compound and medicine comprising the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0083] (1) Synthesis of 10-bromo-1-(4-chlorophenyl)-5-decanol

[0084] Add 5 mL of anhydrous THF to magnesium (591 mg, 24.31 mmol), stir in an argon atmosphere at room temperature, add iodine (10 mg), and stir for 2 hours until the dark brown color almost disappears. 10 mL of an anhydrous THF solution of 4-(4-bromobutyl)chlorobenzene (6.02 g, 24.32 mmol) was added dropwise to the reaction solution for 10 minutes. After the dropwise addition, the mixture was continuously stirred at room temperature for 3 hours to prepare the Grignard reagent.

[0085] 6-Bromohexanal (4.79 g, 49.58 mmol) was dissolved in 10 mL of anhydrous THF with stirring under ice cooling. The prepared Grignard reagent was added dropwise to this solution for 10 minutes. The reaction solution was returned to room temperature, and stirring was continued for 18 hours.

[0086] After the reaction, the reaction solution was water-cooled, and 20 mL of purified water and 20 mL of saturated saline were slowly adde...

Embodiment 2

[0101] (1) Synthesis of 10-bromo-1-(4-chlorophenyl)-3-decanol

[0102] Add 20 mL of anhydrous THF to magnesium (1.07 g, 44.0 mmol), stir in an argon atmosphere at room temperature, add iodine (10 mg), and stir for 2 hours until the dark brown color almost disappears. 20 mL of anhydrous THF solution of 4-(2-bromoethyl)chlorobenzene (9.62 g, 43.8 mmol) was slowly added to the reaction liquid, and stirring was continued for 3 hours to prepare a Grignard reagent.

[0103] 8-Bromo-1-octanal (10.27 g, 49.6 mmol) was dissolved in 30 mL of anhydrous THF under an argon atmosphere with stirring under ice cooling. The prepared Grignard reagent was added dropwise to this solution for 15 minutes. The reaction solution was returned to room temperature, and stirring was continued for 16 hours.

[0104] After the reaction, the reaction solution was water-cooled, and 20 mL of purified water and 20 mL of saturated saline were slowly added, and stirred for 20 minutes. The mixture was extracte...

Embodiment 3

[0121] (1) Synthesis of 2,2-dichloro-12-(4-chlorophenyl) methyl laurate

[0122] Dissolve 2,2-dichloro-12-(4-chlorophenyl)lauric acid (47.3g, 124.5mmol) in 1000mL of methanol, add sulfuric acid (6.10g, 62.19mmol), and heat to reflux and stir for 24 hours.

[0123] After cooling the reaction solution, it was concentrated under reduced pressure, 500 mL of chloroform and 500 mL of water were added, and the organic layer was separated. After the aqueous layer was extracted with chloroform (100m×3), the organic layers were combined, washed with water (200mL), dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to obtain the crude target compound (47.35g, yield 96.6%). Yellow oil.

[0124] 1 H-NMR (CDCl 3 )δ: 1.22-1.40 (12H, m), 1.51-1.62 (4H, m), 2.41 (2H, m), 2.56 (2H, t, J=8Hz), 3.89 (3H, s), 7.10 (2H, d, J=8Hz), 7.23(2H, d, J=8Hz).

[0125] (2) Synthesis of 12-bromo-2,2-dichloro-12-(4-chlorophenyl)methyl laurate

[0126] Dissolve c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Melting pointaaaaaaaaaa
Melting pointaaaaaaaaaa
Melting pointaaaaaaaaaa
Login to view more

Abstract

One uses the following general formula (1): [In the formula, m represents an integer of 0 to 4, n represents an integer of 5 to 9, W represents -CH(OR)- (R represents a hydrogen atom or a hydroxyl protecting group) or -C(=O)-], a salt or an ester thereof, which has the effects of lowering blood sugar, lowering plasma insulin and lowering glyceride, and is very useful for the prevention and/or treatment of diabetes, diabetic complications or hyperlipidemia, etc. .

Description

technical field [0001] The present invention relates to a drug that exhibits strong blood sugar lowering effect, plasma insulin lowering effect and glyceride lowering effect, and is not accompanied by weight gain and obesity, and can prevent and / or treat diabetes, diabetic complications, hyperlipidemia, arterial A carboxylic acid compound for diseases such as sclerosis, and a medicine containing the carboxylic acid compound. Background technique [0002] Diabetes mellitus is a metabolic disease caused by various causes, and is classified into type 1 with insufficient insulin secretion or type 2 with decreased insulin sensitivity in peripheral tissues. Type 2 diabetes, against the background of environmental factors such as obesity and overeating, has increased dramatically in recent years, and the incidence of diabetes in the world is said to be 5%. [0003] Insulin and sulfonylureas are often used in the drug treatment of diabetes, but as a side effect, hypoglycemia and su...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07C59/56A61K31/20A61P3/06A61P3/10A61P9/00A61P29/00C07C59/88C07C69/732C07C69/738
Inventor 井上敬介当间勉北村崇博山崎行由石川哲也
Owner KOWA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap